By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Northern lights chances rise for Christmas as space weather remains unsettled - 2This Week In Space podcast: Episode 189 — Privatizing Orbit
- 3These 2 companies are teaming up to offer insurance for space debris strikes on satellites
- 4Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak
- 5Figure out How to Protect Your Gold Venture from Unpredictability
- Newly identified species of Tanzanian tree toad leapfrog the tadpole stage and give birth to toadlets
- Commonsense Ways to work on Your Funds with a Restricted Pay
- Fundamental Home Items Each Animal person Needs
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Flu is rising rapidly, driven by a new variant. Here's what to know
- Surveys of 6 Hot Savvy Beds
- How to avoid or deal with an outrageous medical bill
- FDA claims on COVID-19 vaccine safety are unsupported by reliable data – and could severely hinder vaccine access
- Jupiter and the moon take a sunset stroll on March 26. Here's how to see it
